Mangalam Drugs & Organics Limited has announced a key leadership change with the resignation of its Chief Financial Officer, effective March 31, 2025. The pharmaceutical company disclosed this development following a Board of Directors meeting held on March 29, 2025.

CFO Resignation Details

The Board of Directors approved the resignation of Mr. Ajay Samant from his position as Chief Financial Officer of the company. The resignation becomes effective from March 31, 2025, marking the end of his tenure with the organization.

Reason for Resignation

The company clarified that Mr. Samant's resignation is due to the attainment of retirement age as per office guidelines. The CFO tendered his resignation on March 28, 2025, which was subsequently presented to the Board of Directors for approval during their meeting on March 29, 2025.

Regulatory Compliance

Mangalam Drugs & Organics acknowledged that it had inadvertently missed mentioning the reason for the CFO's resignation in its initial disclosure. The company has now provided complete information to ensure compliance with regulatory requirements under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The disclosure was made to BSE Limited, where the company's shares are listed under scrip code 532637. The company requested the stock exchange to take note of this information and update their records accordingly.

Mangalam Drugs & Organics Limited (MDOL) has announced a significant development in its international business operations. The company has secured a repeat export order for Anti-Malarial Active Pharmaceutical Ingredient (API) from a reputed international client. This order marks a notable achievement for the company in the global pharmaceutical market.

Order Details

Impact on Company's Position

The receipt of this order is expected to have several positive implications for Mangalam Drugs & Organics Limited:

1. Market Position: This repeat order strengthens the company's position in the global pharmaceutical market, particularly in the anti-malarial segment.

2. Growth Trajectory: The company anticipates that this order may contribute positively to its growth trajectory in the coming quarters.

3. Revenue Visibility: The order is expected to enhance revenue visibility for MDOL in the near term.

Execution and Compliance

Mangalam Drugs & Organics Limited has confirmed that the order will be executed over the next 2-4 months. The company has made this disclosure in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Company's Commitment

In light of this development, MDOL has reiterated its commitment to delivering high-quality pharmaceutical products to both domestic and international clients. This approach aligns with the company's goal of enhancing shareholder value through consistent performance in the global market.

The successful securing of this repeat order suggests a strong relationship with international clients and potentially indicates the quality and reliability of MDOL's Anti-Malarial API products. As the global fight against malaria continues, such orders highlight the important role played by Indian pharmaceutical companies in the international healthcare supply chain.

Investors and market watchers will likely keep a close eye on how this order impacts Mangalam Drugs & Organics Limited's financial performance in the upcoming quarters.